LONDON, UK / ACCESSWIRE / September 27, 2019 / In January, Carmat (Euronext Paris:ALCAR.PA) announced data from the initial 10 patients included in the first leg of its EU pivotal study investigating the surgical implantation of the Carmat heart in patients suffering from end-stage biventricular heart failure (HF). In total, 70% of these patients achieved the primary endpoint, which is survival at six months post implant. Also, improvements to the device manufacturing process starting in Q418 slightly delayed timelines. The trial is expected to resume with the improved Carmat heart in Q319.
We have adjusted our valuation to €856.0m or €68.01 per share from €773m or €83.89 per share. The increase in total value is primarily attributed to rolling forward our NPVs and higher net cash due to an offering. The per-share value fell due to the dilution associated with the offering. We have also delayed our expectations for enrolment completion to H120 (previously mid-2019) and launch in Europe by the end of 2020 (previously H120) due to a temporary halt in device manufacturing.
Click here to view the full report.
Subscribe to Edison’s content to receive reports by email.
All reports published by Edison are free-to-access and available on the website.
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Maxim Jacobs, +1 646 653 7027
Nathaniel Calloway, +1 646 653 7036
SOURCE: Edison Investment Research Limited
View source version on accesswire.com: